Date published: 2026-5-4

1-800-457-3801

SCBT Portrait Logo
Seach Input

GPR32 Inhibitors

GPR32 is an enigmatic member of the G protein-coupled receptor (GPCR) family, which encompasses a diverse group of receptors that play pivotal roles in cellular signal transduction. These receptors respond to a wide array of stimuli, including light, hormones, and neurotransmitters, to regulate various physiological processes. GPR32, like other GPCRs, is presumed to traverse the cell membrane multiple times, creating a binding pocket for potential endogenous ligands. However, unlike many GPCRs that have well-defined roles and ligand interactions, GPR32 remains less understood. The function of GPR32, including its endogenous ligands, signaling pathways, and physiological roles, has not been extensively characterized. Consequently, the understanding of how to modulate its activity, either through activation or inhibition, is limited. Nonetheless, given the significance of GPCRs in cellular communication, gaining insight into the regulation of GPR32 could contribute to a deeper understanding of cellular signaling networks. The exploration of potential inhibitors that could downregulate GPR32 expression involves a speculative approach based on known mechanisms of gene expression modulation. Several chemical compounds, each with distinct cellular targets and actions, might serve as inhibitors by altering the transcriptional or translational machinery of the cell. For instance, compounds that modulate epigenetic markers, such as histone deacetylase inhibitors or DNA methyltransferase inhibitors, could conceivably change the expression level of GPR32 by affecting the accessibility of its gene to the transcriptional machinery. Other chemicals might inhibit key signaling pathways that are crucial for gene expression, such as those mediated by mTOR, MAPKs, or PI3K, which could, in turn, result in decreased expression of GPR32. Each of these pathways plays a role in the complex regulatory network that controls gene expression, and their inhibition could lead to a cascade of changes, potentially altering the expression of a wide array of genes, including those encoding GPCRs like GPR32. It is important to note that these effects are based on broader cellular mechanisms and have not been experimentally confirmed for GPR32. The nuances of GPR32's regulation and expression remain an area ripe for future research to elucidate the precise molecular contexts under which this receptor operates within the cell.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Trichostatin A, a histone deacetylase inhibitor, could downregulate GPR32 expression by altering the chromatin structure around its gene, leading to decreased transcription.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

By inhibiting DNA methyltransferase, 5-Azacytidine may reduce GPR32 gene methylation, potentially decreasing its mRNA synthesis and subsequent protein levels.

ICI 182,780

129453-61-8sc-203435
sc-203435A
1 mg
10 mg
$83.00
$187.00
34
(1)

ICI 182,780 (Fulvestrant), though an estrogen receptor antagonist, could hypothetically decrease GPR32 expression by disrupting potential estrogen receptor-mediated stabilization of GPR32 mRNA.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin could inhibit the mTOR pathway, which may be necessary for GPR32 protein translation, thus leading to reduced protein levels.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059, by inhibiting MEK, could lead to decreased ERK phosphorylation, which may be involved in the transcriptional repression of GPR32.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580, through inhibition of p38 MAPK, could decrease GPR32 expression by hindering p38 MAPK-mediated transcriptional activation of the GPR32 gene.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY 294002, by blocking PI3K, could reduce the activation of AKT, potentially leading to a decrease in GPR32 expression if PI3K/AKT signaling controls GPR32 gene transcription.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 may decrease GPR32 expression by inhibiting JNK, which could be involved in transcriptional activation processes for the GPR32 gene.

Wnt-C59

1243243-89-1sc-475634
sc-475634A
sc-475634B
5 mg
10 mg
50 mg
$214.00
$326.00
$1275.00
1
(0)

Inhibiting the Wnt/β-catenin pathway with Wnt-C59 could lead to decreased transcriptional activation of GPR32 if its expression is Wnt pathway-dependent.

DAPT

208255-80-5sc-201315
sc-201315A
sc-201315B
sc-201315C
5 mg
25 mg
100 mg
1 g
$40.00
$120.00
$480.00
$2141.00
47
(3)

DAPT may reduce GPR32 expression by inhibiting the γ-secretase enzyme, potentially decreasing Notch intracellular domain (NICD) levels and affecting transcription factors that control GPR32 gene expression.